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Melanoma is among the most aggressive cancers, and its rate of incidence
continues to grow. Early detection of melanoma has been hampered due to
the lack of promising markers for testing. Recent advances in liquid biopsy
have proposed noninvasive alternatives for cancer diagnosis and monitoring.
Circulating tumor cells (CTCs) and cancer-exosomes are gaining influence as
promising biomarkers because of their cancer-associated molecular markers
and signatures. However, technologies that offer the dual-isolation of CTCs
and exosomes using a single sample have not been thoroughly developed.
The dual-utilization OncoBean (DUO) device is conjugated with melanoma
specific antibodies, MCAM and MCSP, enabling simultaneous CTC and
exosome isolations. Using blood samples from patients, CTCs and exosomes
are specifically isolated from a single sample and then undergo molecular
profiling for comprehensive study. Melanoma patients have 0–17CTCs mL−1
and 299 µg exosomal protein mL−1 while healthy donors display fewer than
2CTCs and 75.6 µg of exosomes mL−1, respectively. It is also demonstrated
that both markers express melanoma-associated genes using multiplex
qRT-PCR to test for expression pattern of a 96 gene panel. The dual isolation
and molecular characterization will allow for further research into melanoma
to identify viable markers for disease progression and treatment efficacy.
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1. Introduction
Melanoma is one of the most aggressive
cancers whose incidence rate keeps increas-
ing with over 300 000 new cases [1] reported
globally and 100 350 cases projected in the
United States in 2020.[2] Due to the lack of
promising markers to predict the disease
and onset of metastasis, little progress has
been made toward the early detection and
evaluation of treatment efficacy. Early de-
tection of melanoma is critical as early stage
localized melanoma patients have a 98%
survival rate[3] while patients who develop
metastatic melanoma can expect a 5–19%
5-year survival rate.[4] Despite significant re-
search into melanoma metastasis, there is
still a distinct lack of predictive biomarker,
which has in turn led to minimal progress
towards reducing the mortality rate.[2]
Recent advances in the field of liq-
uid biopsies have proposed alternatives
for diagnosing disease with the merits
of enabling continuous monitoring and
non-invasiveness. Circulating tumor cells
(CTCs) and cancer-derived exosomes have
recently evolved as promising biomarkers
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for many cancer types, including lung, prostate, and breast can-
cers, where the cancer-associated molecules correlate to cancer
progression, overall survival, and treatment efficacy. CTCs, shed
from the primary tumor site into blood vessels, are a known
medium of secondary tumor occurrence or metastasis.[5,6] Recent
studies have shown that the presence and number in peripheral
blood is associated with metastatic relapse and tumor burden, as
well as the aggressiveness of cancer and susceptibility to applied
anticancer drugs.[7,8] CTCs in melanoma have also demonstrated
the ability to reflect tumor susceptibility to immune checkpoint
inhibitor treatment.[9]
Despite their advantages, CTC-based melanoma diagnostic or
prognostic tests have not been applied to clinical practice. This is
largely because the only FDA cleared device, CellSearch, is largely
ineffective for isolation melanoma CTCs. CellSearch, and simi-
lar CTC isolation devices, have largely been developed to isolate
CTCs using an antibody against epithelial cell adhesion molecule
(EpCAM), which is downregulated on melanoma CTCs.[10] Since
2011, the CellSearch system has improved for melanoma CTC
detection through the development of the MelCTC kit which re-
places anti-EpCAM with a more melanoma specific melanoma
cell adhesion molecule (MCAM) followed by detection us-
ing an melanoma-associated chondroitin sulfate proteoglycan
(MCSP)/chondroitin-surface proteoglycan 4 (CSGP4)/human
high molecular weight-melanoma-associated antigen (HMW-
MAA) immunostaining panel.[11,12] This research use only kit
has yielded improved results over the original anti-EpCAM
based CellSearch system but 60% of enrolled patients had no
CTCs detected.[13,14] Similar to the MelCTC kit, melanoma CTC
isolation using immunomagnetic beads conjugated with two
melanoma specific antibodies, anti-MCSP and anti-MCAM, has
proven to be effective in isolating over 80% of CTCs in stage IV
melanoma patient blood samples, however its median CTC count
was less than 2 CTCs per ml blood (1.78 CTCs mL−1).[9] CTC con-
centration in melanoma patients using previous methods is often
very low between 0 and 36 per 7.5 mL blood,[13] and thus insuffi-
cient to perform diverse clinical studies such as drug screening
or functional in vitro/in vivo studies.[15] In order to overcome this
drawback, simultaneous isolation of more than one circulating
marker from same patients will allow for further understanding
of melanoma reflecting each circulating marker’s characteristic.
Along with CTCs, exosomes, nanoscale extracellular vesicles
(EVs) actively secreted from malignant cells for cell-to-cell com-
munication, have been used for cancer studies and diagno-
sis. Compared to CTCs, these vesicles are known to be more
stable and abundant in body fluids, which facilitates cancer
studies.[16–18] Recent studies of cancer-derived exosomes have
discovered some of the important roles they play, especially
in tumor progression, such as the transformation of neighbor-
ing cells, acquisition of drug resistance, and transfer of tumor-
associated information to other cells.[19,20] However, a lack of
technologies to isolate and characterize tumor-specific exosomes
has minimalized their use in clinical settings. Thus far, standard
exosome isolation methods, such as ultracentrifugation,[21,22]
polymer-based exosome isolation kits,[23] and immunoaffin-
ity based isolation using antibodies against exosomal surface
proteins,[24,25] have been utilized for tumor exosome isolation.
However, novel specific isolation methods to enrich for specif-
ically tumor-derived exosomes are urgently needed.[26,27] In ad-
dition to the research efforts toward melanoma CTCs, progress
toward the isolation of melanoma-specific exosomes has largely
been made by introducing alternative antibody-capture meth-
ods. Sharma et al. recently provided a way to extract melanoma
specific exosomes from plasma samples using a combination
of isolation methods including size exclusion chromatography
and magnetic beads conjugated with antichondroitin surface
proteoglycan 4 (CSPG4), which targets melanoma cells and
exosomes.[28] They verified the specificity of isolated exosomes
using FACS and showed that the subset of EVs they captured
were melanoma specific and related to immune suppression.
Capture strategies incorporating large antibody cocktails includ-
ing MCSP and MCAM have consistently shown higher results
than single antibody isolation platforms.[29,30] However, these
previous systems still need multiple isolation and incubation pro-
cedures, which hinder an easy isolation of circulating markers.
Also, low capture efficiency and low sensitivity in the isolation of
melanoma circulating markers has demonstrated a need for im-
provements, such as antibody cocktail optimization and its incor-
poration into microfluidics systems, which facilitate highly sen-
sitive isolation from a limited volume of sample.[31–33]
Here, we devised the dual utilization of OncoBean (DUO)
microfluidic device conjugated with melanoma-specific antibod-
ies, MCAM and MCSP, for capturing circulating markers in
an immunoaffinity manner and applied this device to the iso-
lation of both melanoma CTCs (MCTCs) and melanoma exo-
somes (MExos). As both markers originate from the same tumor
sites, coexpression of surface markers allows for identical enrich-
ment strategies.[34,35] Dual marker isolation using the DUO can
yield improved insights due to the distinctive roles they might
play in melanoma progression. Thus, coisolation and analysis
of both markers from a single sample could aid in our under-
standing of the complexities in melanoma progression/diagnosis
and be useful for better diagnosis and monitoring of individ-
ual patients’ clinical status. To this end, MCTCs and MExos are
specifically isolated from patient whole blood samples by iden-
tical devices before undergoing molecular profiling. The radial
flow-based microfluidic device provides all the benefits of tradi-
tional immunoaffinity-based microfluidic devices while allowing
for high sample throughput.[36–38] The inclusion of both isolation
modules in a single platform provides significant convenience
and allows room for future optimization such as attachment of
our labs previously reported inertial force differentiating sample
separation device for rapid and efficient multimarker analysis.[39]
To the best of our knowledge, dual isolation of MCTCs and MExos
from single samples using a single platform has not been studied
yet. This novel device and dual-profiling of melanoma markers
will enable a more comprehensive understanding of the disease,
allowing for enhanced clinical decisions in the future.
2. Results and Discussion
2.1. Strategy for Dual Isolation of MCTCs and MExos Using DUO
Microfluidic Device
The advantages of the microfluidic OncoBean device have
been described in our previous studies mostly involving CTC
isolation.[37,38] Briefly, the OncoBean is a radial flow-based
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Figure 1. Dual-isolation of circulating tumor cells (CTCs) and cancer exosomes via dual-utilization of OncoBean (DUO) microfluidic device: a) schematic
diagram of dual-isolation of CTCs and exosomes from melanoma patient blood samples; b) fabricated DUO microfluidic device with dimensions; c)
relative isolation performance of melanoma cancer cells with two different melanoma antibodies and their combination.
microfluidic device with bean-shape microposts functional-
ized with antibodies to capture targets. The radially placed
micropost design specifically captures target cells expressing
different antigen levels even using high flow rates of up to 10
mL h−1. For this work, two OncoBean modules are combined:
one to isolate MCTCs and one MEXOs that were optimized for
each marker type (Figure 1b). To isolate MCTCs, first module,
CTCBean, was originally conjugated with one of two different
melanoma specific antibodies, anti-MCAM and anti-MCSP, or
a combination of the two. Antibodies against MCSP and MCAM
were chosen as they are the dominant cell surface proteins
on MCTCs.[9] In order to decrease nonspecific bindings, all
devices were blocked with bovine serum albumin (BSA) solution
after antibody conjugation. We compared capture performance
between three different antibody combinations using an MCTC
model sample (SK-MEL-103). We found that MCAM captures
more melanoma cells than MCSP. The MCAM and MCSP
combination showed similar capturing performance as MCAM
on its own (Figure 1c). However, the use of both antibodies was
chosen in order to isolate various melanoma subtypes including
MCSP overexpressed melanoma cells; MCSP expression has
been linked with tumor invasion and serves as an indicator of
poor prognosis in patients.[9,29,40] The specificity of MCSP and
MCAM antibodies also allows for the targeting of specifically
melanoma cancer-derived exosomes for isolation, as over 85%
of melanomas highly express MCSP.[30] The second module,
ExoBean, with MCAM/MCSP antibody conjugation, was also
examined using melanoma patient plasma samples following
passage through 200 nm filter (S1, Supporting Information).
From this study, we found that ExoBeans conjugated with
the MCAM/MCSP cocktail are capable of isolating MExo-like
vesicles more efficiently and more specifically compared to our
device conjugated with the most common exosome antibody,
anti-CD63 (Figure S1, Supporting Information). Following both
capture antibody optimization studies, the anti-MCSP/MCAM
cocktail was chosen as the optimized conjugation for isolation of
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Figure 2. Isolation of circulating melanoma markers using the MCAM/MCSP functionalized DUO device: a) capture efficiencies of melanoma cells
and exosomes from melanoma cell lines, SK-MEL-103, compared to control DUO device without antibody conjugation; b) isolated spiked cancer cells
stained by DAPI and CellTracker green (top) and cancer extracellular vesicles on the device (bottom).
both circulating markers and used in all future studies. After the
verification of MExo isolation, we optimized the flow rate for ex-
osome isolation (Figure S2, Supporting Information) with 1 mL
h−1 showing the best recovery rate of exosome based on a protein
quantity. This flow rate was then used in our clinical studies.
2.2. Dual Isolation of MCTCs and MExos Using Model Samples
Capture efficiencies of the DUO device for both MCTCs and
MExos were tested using SK-MEL-103 cells spiked in whole blood
and SK-MEL-103 derived exosomes spiked in PBS buffer, respec-
tively. The melanoma cell line was prefluoresced with CellTracker
Green to facilitate counting the cells before and after isolation.
For exosome experiments, we spiked a known number of puri-
fied exosomes into filtered PBS and measured the concentration
before and after ExoBean isolation to evaluate capture efficiency.
As shown in Figure 2a, the DUO device demonstrated high cap-
ture efficiencies for both model sample CTCs and exosomes.
The DUO device captured 70% of spiked cancer cells, as well as
75% of exosomes. This capture efficiency exceeds that of previ-
ously reported systems, such as that from Aya-Bonilla et al. whose
two-stage platform produced a 55% capture efficiency in spiked
melanoma CTC samples.[41] Our DUO system also displayed this
selective capture ability even when processing densely populated
samples of 1000 cells mL−1, while the commercially available
MelCTC CellSearch kit delivered a similar 74% capture efficiency
but maxed out at only 160 cancer cells mL−1.[14] The significant
quantity of CTCs and exosomes captured by the DUO device al-
lows for thorough analysis of disease progression through enu-
meration and RNA profiling. Nonfunctionalized control devices
captured significantly reduced numbers of spiked MCTCS (8%)
and MExos (15%). These nonzero efficiencies are likely due to
nonspecific bonding within the chamber, as well as unintended
sized based capture by the microposts within the device.
2.3. Isolation and Evaluation of Circulating Markers from Clinical
Samples
For clinical evaluation of our ExoBean system, we enrolled
15 stage I–IV melanoma patients for quantification and char-
acterization of blood borne MCTC and MExo markers. Both
MCTCs and MExos were isolated from patient peripheral blood
samples using the DUO device with melanoma-specific capture
antibodies and streamlined processing procedures. Whole blood
and prefiltered plasma was used for MCTC and MExo isolation,
respectively. MCTCs were isolated and enumerated using im-
munofluorescence for four staining markers: DAPI, CD45, and a
S100 and melanoma antigen, Melan A. Positive identification of
nucleus and melanoma cells was confirmed by DAPI and S100-
MelanA, respectively, with CD45 distinguishing white blood
cells. Each CTCBean microfluidic device was imaged using
fluorescence microscopy and enumerated were DAPI+/S100+,
Melan A+/CD45- were counted as MCTCs. Figure 3a shows a
representative image of an MCTC captured on a single bean
post along with several leukocytes distinguished by a lack of
Melan A/S100 fluorescence. Isolation of MExos was carried out
from the same set of patient samples as MCTCs. Due to the
small size of exosomes, we used a scanning electron microscope
(SEM) to visualize the MExos captured by an ExoBean. The SEM
results verified the isolation of vesicles on the device surface and
that the size of vesicles are in the range of extracellular vesicles
(Figure 3b). In order to confirm that the vesicles isolated on the
ExoBeans are exosomes, we used western blot analysis to verify
the expression of exosomal markers. This western blot analysis
was performed using three melanoma plasma samples and one
healthy donor sample. As shown in Figure 3c, we verified positive
bands for the exosomal marker CD9 and general housekeeping
protein ß-actin in the three melanoma patient samples tested,
but not in the healthy donor. As the MCAM/MCSP isolation
specifically targets melanoma specific circulating markers, the
increased presence of both general exosomal proteins (CD9) and
general housekeeping proteins (ß-actin) found in melanoma
patient samples would indicate that we are specifically captur-
ing a subset of exosomes that is displaying the target marker
set. This result indicates the presence of exosomes following
MCAM/MCSP isolation of melanoma patient samples but not
healthy donors, and shows that our ExoBean device specifically
targeted and isolated MExos from plasma. For comparison stud-
ies of MExos quantity, MExos isolated on ExoBean devices were
lysed with RIPA solution and measurements of total protein
concentration were obtained by western blot.
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Figure 3. Evaluation of isolated melanoma circulating tumor cells and melanoma-associated exosomes by MCAM/MCSP functionalized OncoBean
devices; a) circulating melanoma cell stained by DAPI(nucleus), CD45(leukocyte), and cocktail of Melan-A and S100 (melanoma); b) scanning electron
microscopy image of isolated exosome-like vesicles on the OncoBean device; c) western blot analysis of exosomes isolated by DUO (ExoBean).
2.4. Dual Profiling of MCTCs and MExos Using Clinical Samples
2.4.1. Quantitative Analysis in MCTCs and MExos from Clinical
Samples
Quantitative analysis of MCTCs and MExos captured by DUO
devices is shown in Figure 4. We first compared the MCTC num-
ber and total MExo protein amounts for each sample, normal-
ized to 1 mL of starting blood (Figure 4a). The present devices
captured an average of 5.5 MCTCs per mL of blood in melanoma
patients, compared to just 0.3 MCTCs per mL in healthy donors
(Figure 4b). Total MExo protein from each device is also shown in
Figure 4b. Melanoma patients demonstrated significantly more
melanoma tumor derived exosomes than healthy donors, aver-
aging 299 µg of protein per mL of plasma compared to only
75.6 µg mL−1 in healthy controls. All MCTC number and total
exosomal protein quantity results were normalized to 1 mL of
blood per sample. Statistical analysis comparing quantity differ-
ences in patient samples compared to healthy donors for both
MCTCs and MExos was performed using t-tests. The results of
these tests show that the difference in isolated MCTC number
was statistically significant (p-value 0.00451), while the differ-
ence in protein found using MExos was statistically insignifi-
cant (p-value 0.2358). MCTC concentration and total exosomal
protein amounts in each patient were analyzed and compared.
There is no discernable correlation between MCTC quantity
and total exosomal protein amount among those tested. Thus,
any test result indicating MCTC concentration or exosomal pro-
tein quantity should not serve as a reliable indicator for the
other.
2.4.2. Gene Panel Analysis of MCTCs and MExos from Clinical
Samples
We next examined RNA quantities from the isolated MCTCs
and MExos within each patient. After isolation of either CTCs
or exosomes, RLT buffer (Qiagen, USA) was applied to each
device for lysis and extraction of RNA. These RNA samples were
then analyzed using Bioanalyzer. Results for RNA quantity in
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Figure 4. Comparison between results from CTCs and exosomes in melanoma patients; a) comparison of CTC number and total exosomal protein
quantity per 1 mL of blood sample; b) average CTC numbers and exosomal protein quantities between melanoma and healthy donors; c) RNA quantities
comparison from CTC lysates and exosome lysates.
captured samples are shown in Figure 4c and are normalized
to show RNA per mL of blood for both MCTCs and MExos. For
each patient tested, exosome RNA concentration was higher
than that found from CTCs. This higher RNA concentration for
EVs demonstrates a potential benefit as a marker over CTCs, as
less biological fluid is needed for sampling from each patient. As
devices with lower fluid requirements yield more practicality in
liquid biopsy, exosomes present an exciting alternative to CTCs
in this regard. Unpaired t-tests comparing melanoma patient and
healthy donor sample sets were then performed for both MCTCs
and MExos. As shown in Figure S3 (Supporting Information),
these t-tests returned nonsignificant differences for MCTCs
(p-value 0.7413) and MExos (p-value 0.4595). However, these re-
sults are likely due to the small sample sizes used for the healthy
donors (n = 4) compared to clinical samples (n = 15) which
makes the data more sensitive to error. In future, increasing the
number of healthy donor samples may alleviate this sensitivity.
We then examined specific gene expression levels within each
sample. The SINGuLAR platform was used to generate clus-
tered and unclustered heat maps to identify the most signifi-
cant differentially expressed genes between the CTCs of patient,
healthy and control samples (Figure 5a). Violin plots were also
generated using the collected expression data and are shown in
Figure S7 (Supporting Information). In total, gene expression
data were compiled from MCTCs isolated from 15 melanoma
patients, 4 healthy donors, and SK-Mel-103 cell line as a con-
trol. In line with our initial hypothesis and previous research,
CTCs highly express standard housekeeping genes, like GAPDH,
ACTB and HSPA1. In comparing patient samples with healthy
donors (Figure S4, Supporting Information), differences in ex-
pression were noted for some genes. In melanoma patient CTCs,
𝛽2-microglobulin (B2M) gene expression was nearly treble that
found in healthy donor samples. B2M has been linked with the
regulation of tumor growth and metastasis in several common
cancers.[42] Another gene with increased expression in tested pa-
tient samples was that of matrix Gla protein (MGP). Increased
MGP gene expression has been related to poor patient progno-
sis in cancers such as breast cancer.[43] The plots in Figure 5b
show notable MGP expression amongst melanoma patient sam-
ples, while no MGP expression was found in any of the healthy
donors. We also see a high expression profile for the CD63 gene
in our melanoma patients, at nearly double that found in healthy
donors. Increased CD63 expression which has been correlated
with early stage melanoma tumor progression in other studies.
Studies have also shown the expression of CD9 gene to be in-
versely related to the metastatic potential of melanoma. Our data
indicates CD9 expression for the patient samples, however not
much can be said about the metastatic potential of the tumor in
each case. Some of the other genes on the panel which showed a
high expression profile in melanoma patients but not in healthy
donors were MTOR, BAP1, CDH1, FAM3C, and TP53.
While significant focus was placed on differences in specific
gene expression levels found between melanoma patient and
healthy donor CTCs, we also note several genes that showed sim-
ilar expression levels amongst all CTC samples. For example, a
number of examined genes were highly expressed in both patient
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Figure 5. Gene panel analysis of melanoma CTCs (MCTCs) and melanoma exosomes (MExos) isolated by DUO; a) heatmap analysis of gene expression
on MCTCs recovered from melanoma patients, healthy donors and melanoma cell line, SK-MEL-103; b) violin plot analysis of gene expression on MCTCs;
c) heat map analysis of gene expression on MExos recovered from melanoma patients, healthy donors and cell line derived exosomes; d) violin plot
analysis of gene expression on Mexos; e) pair-wise comparison between MCTCs and MExos from same samples.
and healthy donor CTC samples, including CXCL8, S100A8,
S100A9, ALDH1A1, and RxRA. This result is noteworthy, as
increased expression of each of these five genes has indepen-
dently been linked to tumor cell growth and/or poor prognosis in
various common cancers, including melanoma. In both patient
and healthy samples tested, we see a low expression of the gene
ALDH1A3, which has been associated with the stemness of both
cancer stem cells and normal tissue stem cells. Recent reports
reveal that ALDH1A3 is a useful cancer stem cell marker that
can be used to enrich tumor-initiating subpopulations from
various cell lines and primary tumors.[44] The EGFR gene, which
is often associated with lung cancer, had a low expression profile
for the CTCs in our study. Low LIF expression levels have been
shown to promote cell differentiation, and we observed a very
low expression profile for LIF in our CTC patient samples. Some
of the other genes which displayed a low expression profile in all
samples tested were WNT5A, S100A1, TYRP1, and HxB/TNC.
The gene analysis data for exosome samples was handled in a
manner similar to the CTC samples and was tested against the
same 96 gene panel with (Figure 5c and Figure S8, Supporting
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Information). In comparing exosome gene results between
patient and healthy donor samples, we find that patient sam-
ples had notably more expression of the protein coding gene
Vimentin. As shown in Figure 5d, median Vimentin expression
in melanoma patient samples was double that of healthy donors.
Increased Vimentin expression in epithelial cancers including
melanoma has been shown in previous studies, with the protein
itself used as a general cancerous exosome marker in cancers
such as lung cancer.[45] We also noticed a general increase in ex-
pression level of CD271 in melanoma patient exosome samples
compared to healthy donors. This would make sense as CD271
has previously been proposed as a melanoma marker due to
high observed occurrence and indicates increased stemness and
tumorigenicity.[46,47] Another gene we saw greater expression
in patient exosome samples than in healthy donor samples was
CD29. This increased expression is noteworthy due to the impli-
cation of CD29 in the metastatic diffusion of tumors in previous
studies.[48] Several genes showed similar expression between
healthy donors and patients, such as significant expression of
GAPDH, ACTB, B2M, and UBB across most tested samples. We
also found no expression of ALDH1A3, EGFR, KRT14, CD11,
and PDL-1 genes in any of the exosome samples from patients or
healthy donors. Patient M11 Exo shows higher gene expressions
than the rest of the patients, when compared to the healthy
donors’, including genes HSPA1, UBB, and KFB1. HSPA1
is known to be highly expressed in several cancers, including
melanoma, and is associated with cancer development and
progression. Elevated levels of the UBB gene are shown to be
essential for the growth of cancer cells. Here we observed genes
S100A9 and S100A8 with high expression profiles. S100A9 has
been associated as a key factor in cancer development and tumor
spread. While the gene LIF had a low expression in CTCs, we
see a very high expression profile for the same gene in exosome
samples. FAM3C, GAPDH, Vimentin, and Annexin are a few
among the other genes to have high expression profiles. Unlike
in the CTC samples, CAV1 and HSPA1 have very low expression
in the exosome samples. In comparing results from Figure 5c
with total exosome RNA quantity in each sample, there appears
to be a correlation between high total RNA quantity and high
(gene right above CD20 in the panel) expression.
2.4.3. Correlation between MCTCs and MExos in Melanoma
A comparison between MCTC and MExo gene expression in each
patient is displayed in Figure 5e. These results show significantly
lower overall gene expression in MExos compared to MCTCs in
most patient samples. Exosomes are known for carrying dam-
aged, or degraded mRNA and only contain prepackaged RNA
from the cell of origin. However, they are also plentiful and re-
leased from all portions of the tumor leading to increased special
sampling, whereas the 0–100 CTCs isolated will not represent the
entire tumor. Therefore, while the number of genes expressed,
and the magnitude differences in log fold change in exosomes
may not be as high as CTCs, they offer the potential for a more
holistic snapshot of the tumor. There are a couple notable excep-
tions to this trend, as seen with patient M11 displaying significant
gene expression in both MCTCs and MExos, and in patients M10
and M13 who show little to no expression of the entire gene panel
within either marker. Another divergence from this trend can be
found with the Vimentin gene, which showed similar expression
in both CTC and exosome sample across most patients. Simi-
lar MCTC and MExo sample gene expression can also be found
with B2M and UBB, and ACTB. Overall, gene expression within
MCTC patient samples closely resembles that of SK-MEL-103 cell
line CTCs, while the low gene expression found in patient MExos
breaks significantly from the high gene expression displayed on
SK-MEL-103 cell line derived exosomes. Clinical samples, such
as M8 CTC and M12 CTC show similar gene expression pattern
to exosome cell line SK-MEL-103. CD63 and B2M genes are com-
monly expressed in both the clinical samples and SK-MEL-103.
B2M gene has functions of cancer cell growth, and CD63 gene
has shown to be correlated with cell development and tumor pro-
gression.
The present comparison study only used a 96 gene panel that
was designed for cellular probing, in fact a different set of genes
would likely be found in exosomes compared to cells. Future
work would include enhancing our RNA profiling to RNA-seq, or
mRNA microarrays that offer more widespread gene profiling.
3. Conclusion
In this study, we have demonstrated the potential of simul-
taneous isolation of MCTCs and MExos from a single sam-
ple using the DUO device. This devices utilization of the
MCAM/MCSP antibody cocktail allows for more specific MCTC
isolation than offered by widely used single marker methods.
The specificity offered by the DUO device allowed us to show
that melanoma patients average slightly over 5 MCTCs per mL
of blood, while healthy blood contains no MCTCs. Along with
capturing MCTCs, the importance of specifically isolating exo-
somes from melanoma patients is emphasized by our finding
that MExos contain a higher RNA concentration than MCTC
samples, thus making MExos a potentially more efficient marker.
Additionally, using the DUO device, we were able to establish
increased MCAM/MCSP expressing exosome protein concentra-
tion as a marker for the presence of melanoma. Overall, the abil-
ity to isolate MCTCs and MExos with high sensitivity as high
throughput from melanoma patient blood samples provides clin-
icians a powerful and versatile tool for gauging disease progres-
sion and treatment response.
4. Experimental Section
Melanoma Cell Culture and Model Sample Preparation: In order to pre-
pare model samples for melanoma cells, SK-MEL-103 cell line was used.
The SK-MEL-103 cells were cultured in conditioned media and around
5000 cells were spiked into 1 mL of PBS buffer solution or whole blood
sample. Besides model samples for MCTCs, cell line derived exosomes
were prepared by ultracentrifugation of SK-MEL-103 cell culture super-
natant with exosome depleted fetal bovine serum. After ultracentrifuga-
tion, exosome concentration was measured using NanoSight NS300 (Mar-
ven Instruments, UK), and known exosome concentrations were used for
model sample preparation.
Clinical Sample Preparation: The sample collection and experiments
were approved by Ethics committee (Institutional Review Board and Scien-
tific Review Committee) of the University of Michigan. Informed consents
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were obtained from all participants of this clinical study and melanoma
blood samples were obtained after approval by the institutional review
board at the University of Michigan (HUM00105509). All experiments
were performed in accordance with the approved guidelines and regula-
tions of the ethics committee at the University of Michigan. Whole blood
was collected from the University of Michigan cancer center. Roughly 6
mL of whole blood was used for CTC capture per sample, while the re-
maining blood was processed to collect plasma for exosome isolation.
Plasma collection was carried out using 5810R centrifuge (Eppendorf, Ger-
many). Blood was centrifuged at 2000 × g for 15 min, allowing for separa-
tion of plasma from blood cells. Another centrifugation at 12 000 × g was
conducted to remove all residual cellular debris. The supernatant plasma
sample was filtered through a 200 nm syringe filter and deposited into 2
mL vials. The vials were then stored at −80 °C for future use.
DUO Chip Fabrication and Surface Modification for Melanoma: DUO
chip fabrication procedure was previously described[37,38] and this proce-
dure was followed with modifications for MExo capture. The PDMS mold
was bonded to a glass slide using O2 plasma treatment (Covance, Femto
Science, South Korea). Following bonding, each device was placed on a hot
plate at 80 °C for 10 min, then allowed to cool to room temperature. A so-
lution of 500 µL Silane in 5 mL ethanol was injected into each device every
15 min for a total of an hour, followed by a pure ethanol wash. GMBS cross
linker solution (14 µL GMBS in 5 mL ethanol) was then injected into the de-
vice and incubated for 30 min, followed by another ethanol wash. NeutrA-
vidin solution (500 µL NeutrAvidin in 5 mL PBS) was injected into each de-
vice before the devices were parafilm sealed into Petri dish containers and
stored at 4 °C for future use. The prepared DUO devices were conjugated
with melanoma associated antibodies MCAM (Miltenyi Biotec, Germany)
and MCSP (Novus, USA). 200 µL of antibody solution (2.5 µL MCAM and
2.76 µL MCSP in 250 µL 1%BSA) were injected into each device and incu-
bated 1 h. The devices were then washed with PBS and blocked with either
3% or 1% BSA solution for CTC or exosome capture, respectively. The de-
vices were now prepared to accept samples and capture target CTCs and
exosomes.
Dual Isolation of CTCs and Exosomes: For CTC isolation, 3 mL of whole
blood was slowly applied to each antibody-conjugated device using an
auto-pump (PHD 2000, Harvard Apparatus, USA) at a flow rate of 5 mL
h−1. Blood remaining in the devices was then immediately washed out
using PBS. Devices were then prepared for either DNA/RNA analysis or
immunostaining for imaging. Simultaneously, MExo isolation took place
by injecting a 1 mL plasma sample into the device using the syringe pump
at a low flow rate of 1 mL h−1. Unbound exosomes were then washed out
using PBS. Devices with captured exosomes were then prepared for either
nucleic acid or protein extraction for sample analysis.
Immunostaining of CTCs from Melanoma: After blood samples were
applied and washed out, devices were fixed with 1 mL of 4% PFA so-
lution. PFA fixation solution was allowed to incubate for 40 min before
being washed out with PBS. Each device was then permeabilized with 1
mL of 0.2% Triton solution and incubated 30 min. Triton was then re-
moved by PBS wash before the application of 1 mL 3% BSA-2% normal
goat serum solution (500 µL 6%BSA, 200 µL normal goat serum, 300
µL PBS), which was incubated for 30 min. Primary staining antibody so-
lution composed of 10 µL anti-Melan-A/MART1 (R&D Systems, USA,) 25
µL S100 (mouse IgG2a, ThermoFisher, USA,) and 25 µL CD45 (rat IgG2b,
Santa Cruz Biotech, USA) in 1 mL of 1%BSA was pumped into each device
and incubated for 1 h. Excess primary antibody solution was removed by
PBS wash. A secondary staining antibody solution was then applied con-
taining 5 µL AlexaFluor 546 (goat anti-mouse IgG2a, Life Technologies,
USA) and 5 µL AlexaFluor 488 (goat anti-rat IgG, Life Technologies, USA)
in 1 mL of 1%BSA and allowed to incubate for 1 h in the dark. Excess sec-
ondary antibodies were removed by PBS wash followed by the application
of 1ml DAPI staining solution (1 µL DAPI in 1 mL 1%BSA.) The DAPI solu-
tion was incubated for 15 min followed by a final PBS wash. Devices were
imaged using Ti2 microscope (Nikon, Japan) at 10× magnification for cell
analysis. Images taken in FITC, DAPI, and CY3 fluorescence.
Field Emission Scanning Electron Microscopy (FE-SEM): Following exo-
some isolation, some devices were sampled using a biopsy punch and a
razor blade cutter with previously defined SEM sampling procedures,[49]
with extracted PDMS specimens rinsed with PBS followed by dehydra-
tion with increasing concentrations of ethanol (50%, 70%, 90%, 95%, and
100%). The specimens were then incubated with hexamethyldisilazane
(Sigma-Aldrich, USA) in a fume hood overnight to dry. The dehydrated
specimens were mounted on SEM stubs with carbon conductive tape and
silver paint, and then sputter-coated with a layer of gold. Exosomes cap-
tured by the ExoBean were then examined by FEI Nova 200 Nanolab Du-
albeam FIB scanning electron microscope under low beam energies (2.0–
5.0 kV) at the Electron Microscopy Analysis Lab (MC2) at University of
Michigan.
Nanoparticle Tracking Analysis: Evaluation of the exosome concentra-
tion and size distribution was analyzed by nanoparticle tracking analysis
(NTA) using NanoSight NS300 (Marven Instruments, UK). 30 µL of the
initial model sample solution or postcapture sample solution was applied
to the jig of the system, and a laser module was mounted inside the main
instrument housing. NTA visualizes the scattered lights from the particles
of interest based on their Brownian motion. This movement was moni-
tored through a video sequence for 20 s in triplicate. All data acquisition
and processing were performed using NanoSight NS300 control software,
and concentration of particles in exosome sizes was compared to that of
initial samples for calculating capture efficiencies of the ExoBean.
Exosomal Total Protein Quantification and Western Blotting: After ex-
osome capture experiments, RIPA buffer (ThermoFisher, USA) was then
processed through the device for the lysis of exosomes membrane to har-
vest the exosomal protein. Total exosomal protein quantity was measured
using micro BCA kit (ThermoFisher, USA).
Total Nucleic Acid Extraction: The captured cells and vesicles were
lysed on chip immediately after PBS washing using RLT buffer (RLT Plus
RNeasy Plus lyses, Qiagen, Germany). Inlet and outlet tubing was con-
nected to a sterile 1.5 mL vial and RLT buffer was injected into the inlet.
All effluents were stored at −80 °C until RNA analysis. The RNA quanti-
ties in the whole lysate was evaluated and 5 ng µL−1 of the total RNA for
each sample was used to make cDNAs. cDNA synthesis was followed us-
ing Cell-to-CT kit (Invitrogen, USA) following the manufacturer’s protocol.
cDNA which was preamplified for the target 96 genes was diluted with 20×
GE sample loading reagent (Fluidigm, USA) and used to analyze gene ex-
pression by the Biomark HD system (Fluidigm, USA).
Melanoma 96-Gene Panel Expression Analysis for CTCs and Exosomes:
The preamplified cDNA was subjected to qPCR to determine expression
patterns of target 96 genes, “Melanoma CTC/Exo gene panel,” using Taq-
Man assays and the Biomark HD instrument. The assay was performed fol-
lowing the manufacturer’s protocol with optimizations for this study. After
processing, Raw Ct values generated by Biomark HD (Fluidigm) were an-
alyzed using the SINGuLAR toolset (Fluidigm, USA) and R script to deter-
mine the expression pattern of the panel of 96 genes for each sample.[50,51]
Undetected transcripts automatically generate a Ct value of 999, which
were changed to Ct of 40 for numerical analyses.
[50,51] Statistical analysis
was performed using R software.
SINGuLAR Platform for CTCs and Exosomes: The SINGuLAR Analysis
Toolset was chosen to study the gene expression profile of the CTC and ex-
osome patient samples. This platform supports the gene expression analy-
sis on the qRT-PCR data from the BiomarkHD system. A panel of 96 genes
was selected to understand the variations in gene expression between the
patient, control and healthy samples. Gene expression data set for each
sample is processed according to the guidelines of the SINGuLAR man-
ual before statistical analysis of the data. The raw mRNA expression data
from BiomarkHD was grouped and processed in a manner that allows for
a thorough comparative study of the single gene expression in CTCs and
exosomes for the same patient. The approach adopted in this study also
successfully highlights the general trend of gene expression for CTCs and
Exosomes and their key variations from the healthy patient samples and
the cell line control. Statistical tools of ANOVA and principal component
analysis (PCA) were employed to identify the most significant markers out
of the 96 genes studied. Heatmap clustering (based on global z score),
violin and box plots have been used to visualize this data.
Statistical Analysis: All results present as mean ± standard deviation.
Statistical analysis was demonstrated using Prism software. Unpaired t-
tests (two-tailed) were used to compare the differences between total
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CTCs and exosomal quantities of melanoma patients (n = 15) versus
healthy controls (n = 4). The same statistical test was used for RNA quan-
tity comparison in CTCs and exosomes between melanoma patients (n =
15) and healthy controls (n = 4). Statistical significance was defined as a
two-tailored p < 0.05. Gene expression analysis was conducted using the
SINGuLAR Analysis Toolset (Fluidigm), which is operated through R. Sta-
tistical tools of ANOVA and principal component analysis (PCA) were em-
ployed to identify the most significant markers out of the 96 genes studied.
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